Asset Details
Do you wish to reserve the book?
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Do you wish to request the book?
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
2018
Overview
Cytokine release syndrome (CRS) is a life-threatening complication of several new immunotherapies used to treat cancers and autoimmune diseases
1
–
5
. Here we report that atrial natriuretic peptide can protect mice from CRS induced by such agents by reducing the levels of circulating catecholamines. Catecholamines were found to orchestrate an immunodysregulation resulting from oncolytic bacteria and lipopolysaccharide through a self-amplifying loop in macrophages. Myeloid-specific deletion of tyrosine hydroxylase inhibited this circuit. Cytokine release induced by T-cell-activating therapeutic agents was also accompanied by a catecholamine surge and inhibition of catecholamine synthesis reduced cytokine release in vitro and in mice. Pharmacologic catecholamine blockade with metyrosine protected mice from lethal complications of CRS resulting from infections and various biotherapeutic agents including oncolytic bacteria, T-cell-targeting antibodies and CAR-T cells. Our study identifies catecholamines as an essential component of the cytokine release that can be modulated by specific blockers without impairing the therapeutic response.
Atrial natriuretic peptide, an anti-inflammatory protein, can protect against cytokine release syndrome induced by therapeutic agents such as tumour-targeting bacteria and CAR-T cells by blocking catecholamine synthesis by macrophages.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 13/21
/ 59/5
/ 631/67
/ 64/110
/ alpha-Methyltyrosine - pharmacology
/ Analysis
/ Animals
/ Antigens
/ Atrial Natriuretic Factor - pharmacology
/ Bacteria
/ Catecholamines - antagonists & inhibitors
/ Catecholamines - biosynthesis
/ CD3 Complex - antagonists & inhibitors
/ Control
/ Dopamine
/ Female
/ Genomes
/ Humanities and Social Sciences
/ Humans
/ Kinases
/ Letter
/ Leukemia
/ Male
/ Mice
/ Myeloid Cells - drug effects
/ Peptides
/ Receptors, Antigen, T-Cell - genetics
/ Receptors, Antigen, T-Cell - metabolism
/ Receptors, Antigen, T-Cell - therapeutic use
/ Rodents
/ Science
/ Sepsis
/ Syndrome
/ T-Lymphocytes - drug effects
/ Tumors
/ Tyrosine
